To test this hypothesis, in the current study we determined the effect of treatment with the selective PRMT5 inhibitor GSK3326595 on (1) the macrophage response to pro‐inflammatory stimuli in vitro and ex vivo and (2) atherosclerosis development in hypercholesterolemic low‐density lipoprotein (LDL) receptor knockout mice in vivo. This evidence concerns the gene PRMT5 and atherosclerosis.